CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 – 6, 2023, in Chicago, Illinois.
The abstracts are currently available on the ASCO meeting website. The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.
Poster Presentation Details:
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
CONTACT:
Public Relations Dept.,
Actuate Therapeutics, Inc.
+1 (847) 986-4190
info@actuatetherapeutics.com
TORONTO, ON / ACCESSWIRE / April 5, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero"…
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…
LAS VEGAS, NV / ACCESSWIRE / April 5, 2024 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNH)…
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilitiesTORONTO, April 05, 2024 (GLOBE NEWSWIRE)…
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway…